These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35095075)

  • 61. Ivabradine for the Treatment of Acute Mitral-Regurgitation-Related Decompensated Heart Failure.
    Lee WC; Fang HY
    Cardiology; 2019; 144(3-4):97-100. PubMed ID: 31533098
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction.
    Valika A; Paprockas K; Villines D; Costanzo MR
    Clin Cardiol; 2018 Jun; 41(6):752-757. PubMed ID: 29512170
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
    O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ
    Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction.
    Sengeløv M; Jørgensen PG; Jensen JS; Bruun NE; Olsen FJ; Fritz-Hansen T; Nochioka K; Biering-Sørensen T
    JACC Cardiovasc Imaging; 2015 Dec; 8(12):1351-1359. PubMed ID: 26577264
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
    Zugck C; Martinka P; Stöckl G
    Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
    Ozturk S; Öztürk S; Erdem FH; Erdem A; Ayhan S; Dönmez İ; Yazıcı M
    J Interv Card Electrophysiol; 2016 Sep; 46(3):253-8. PubMed ID: 27039084
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of Heart Rate Reduction With Either Pyridostigmine or Ivabradine in Patients With Heart Failure: A Randomized, Double-Blind Study.
    Villacorta AS; Villacorta H; Caldas JA; Precht BC; Porto PB; Rodrigues LU; Neves M; Xavier AR; Kanaan S; Mesquita CT; da Nóbrega ACL
    J Cardiovasc Pharmacol Ther; 2019 Mar; 24(2):139-145. PubMed ID: 30198318
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study).
    Fu M; Ahrenmark U; Berglund S; Lindholm CJ; Lehto A; Broberg AM; Tasevska-Dinevska G; Wikstrom G; Ågard A; Andersson B;
    Clin Res Cardiol; 2017 Dec; 106(12):960-973. PubMed ID: 28795299
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.
    Givertz MM; Stevenson LW; Costanzo MR; Bourge RC; Bauman JG; Ginn G; Abraham WT;
    J Am Coll Cardiol; 2017 Oct; 70(15):1875-1886. PubMed ID: 28982501
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?].
    Kanorskiy SG; Borisenko YV
    Kardiologiia; 2018 Jun; 58(6):85-89. PubMed ID: 30362441
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
    Lopatin YM; Cowie MR; Grebennikova AA; Sisakian HS; Pagava ZM; Hayrapetyan HG; Abdullaev TA; Voronkov LG; Chesnikova AI; Tseluyko VI; Tarlovskaya EI; Dadashova GM; Berkinbaev SF; Glezer MG; Koziolova NA; Rakisheva AG; Kipiani ZV; Kurlyanskaya AK
    Int J Cardiol; 2018 Jun; 260():113-117. PubMed ID: 29622423
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prediction of heart failure and adverse cardiovascular events in outpatients with coronary artery disease using mitral E/A ratio in conjunction with e-wave deceleration time: the heart and soul study.
    Mishra RK; Devereux RB; Cohen BE; Whooley MA; Schiller NB
    J Am Soc Echocardiogr; 2011 Oct; 24(10):1134-40. PubMed ID: 21764551
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial.
    Nguyen LS; Squara P; Amour J; Carbognani D; Bouabdallah K; Thierry S; Apert-Verneuil C; Moyne A; Cholley B
    Crit Care; 2018 Aug; 22(1):193. PubMed ID: 30115103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic value of a restrictive mitral filling pattern in patients with systolic heart failure and an implantable cardioverter-defibrillator.
    Bruch C; Gotzmann M; Sindermann J; Breithardt G; Wichter T; Böcker D; Gradaus R
    Am J Cardiol; 2006 Mar; 97(5):676-80. PubMed ID: 16490436
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction.
    Rusinaru D; Houpe D; Szymanski C; Lévy F; Maréchaux S; Tribouilloy C
    Eur J Heart Fail; 2014 Sep; 16(9):967-76. PubMed ID: 25111982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.